pISSN 1226-6051
eISSN 2508-786X

Table. 1.

Table. 1.

Demographic information (n=2,992)

Characteristic All (n=2,992) Two pill combination (n=1,915, 64%) Fixed dose combination (n=1,077, 36%) p value

Number (%) Number (%) Number (%)
Sex 0.332
Male 1,75 (58.7) 1,112 (63.3) 645 (36.7)
Female 1,235 (41.3) 803 (65.0) 432 (35.0)
Age(years) 0.616
20-39 273 (9.1) 169 (61.9) 104 (38.1)
40-49 637 (21.3) 419 (65.8) 218 (34.2)
50-59 1,064 (35.6) 672 (63.2) 392 (36.8)
60-69 742 (24.8) 471 (63.5) 271 (36.5)
≥70 276 (9.2) 184 (66.7) 92 (33.3)
Comorbidity
Dyslipidemia 2,681 (89.6) 1,714 (63.9) 967 (36.1) 0.808
Gastrointestinal disease 2,208 (73.8) 1,427 (64.6) 781 (35.4) 0.232
Hypertension 1,785 (60.0) 1,164 (65.2) 621 (34.8) 0.095
Diabetic neuropathy 557 (18.6) 392 (70.4) 165 (29.6) 0.001
Diabetic retinopathy 429 (14.3) 302 (70.4) 127 (29.6) 0.003
Coronary artery disease 326 (10.9) 209 (64.1) 117 (35.9) 0.966
Heart failure 165 (5.5) 112 (67.9) 53 (32.1) 0.286
Stroke 93 (3.1) 60 (64.5) 33 (35.5) 0.917
Chronic kidney disease 45 (1.5) 35 (77.8) 10 (22.2) 0.052
Insurance 0.571
NHI 2,827 (94.5) 1,803 (63.8) 1,024 (36.2)
MedAid/PVI 165 (5.5) 112 (67.9) 53 (32.1)
Institution <0.001
Tertiary hospital 414 (13.8) 308 (74.4) 106 (25.6)
General hospital 750 (25.1) 515 (68.7) 235 (31.3)
Clinic 1,623 (54.2) 950 (58.5) 673 (41.5)
Others 205 (6.9) 142 (69.3) 63 (30.7)
Specialty 0.064
Internal medicine 2,808 (93.9) 1,812 (64.5) 996 (35.5)
Family medicine 107 (3.6) 60 (56.1) 47 (43.9)
Others 77 (2.6) 43 (55.8) 34 (44.2)
Area 0.023
Seoul 656 (22.0) 410 (62.5) 246 (37.5)
Kyeonggia 908 (30.3) 585 (64.4) 323 (35.6)
Gyeongsangb 660 (22.1) 437 (66.2) 223 (33.8)
Jeollac 299 (10.0) 170 (56.9) 129 (43.1)
Chungcheongd 341 (11.4) 232 (68.0) 109 (32.0)
Gangwon 91 (3.0) 53 (58.2) 38 (41.8)
Jeju 37 (1.2) 28 (75.7) 9 (24.3)

NHI, National Health Insurance; MedAid, Medical Aid; PVI, Patriots and Veterans Insurance

a Kyeonggi-do and Incheon Metropolitan City are included

b Kyeongsangnam-do, Kyeongsangbu-do, Busan Metropolitan City, Ulsan Metropolitan City and Daegu Metropolitan City are included.

c Jeollanam-do, Jeollabuk-do and Gwangju Metropolitan City are included

d Chungcheongnam-do, Chungcheongbuk-do and Sejong City are included

Korean J Clin Pharm 2022;32:13-9 https://doi.org/10.24304/kjcp.2022.32.1.13
© 2022 Korean J Clin Pharm